Douglas Thomson
Company: Proxygen
Job title: Principal Scientist, Director & Head of Medicinal Chemistry
Seminars:
Leveraging Selective Inhibition of CDK12/13 Through Degradation of Cyclin K 9:30 am
Outlining how targeted protein degradation of cyclin K enables discovery of highly selective kinase inhibitors Presenting how event-driven pharmacology drives potency and selectivity Exploiting the PK/PD disconnect for use to further enhance selectivity window in vivoRead more
day: Conference Day Two